MXPA06004136A - Compounds having crth2 antagonist activity - Google Patents
Compounds having crth2 antagonist activityInfo
- Publication number
- MXPA06004136A MXPA06004136A MXPA/A/2006/004136A MXPA06004136A MXPA06004136A MX PA06004136 A MXPA06004136 A MX PA06004136A MX PA06004136 A MXPA06004136 A MX PA06004136A MX PA06004136 A MXPA06004136 A MX PA06004136A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- fluoro
- indol
- acetic acid
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 186
- 230000000694 effects Effects 0.000 title claims description 20
- 230000003042 antagnostic Effects 0.000 title claims description 14
- 239000005557 antagonist Substances 0.000 title claims description 12
- 208000006673 Asthma Diseases 0.000 claims abstract description 14
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 10
- 229940002612 prodrugs Drugs 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims abstract description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 8
- 239000012453 solvate Substances 0.000 claims abstract description 3
- -1 -O-aryl Chemical group 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 42
- BHMBVRSPMRCCGG-OUTUXVNYSA-N Prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 230000001404 mediated Effects 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 9
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 9
- 229940079593 drugs Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 206010003816 Autoimmune disease Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 230000000051 modifying Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000000699 topical Effects 0.000 claims description 5
- 206010000496 Acne Diseases 0.000 claims description 4
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 206010011401 Crohn's disease Diseases 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
- 208000008585 Mastocytosis Diseases 0.000 claims description 4
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 4
- 206010039095 Rhinitis seasonal Diseases 0.000 claims description 4
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 4
- 235000020932 food allergy Nutrition 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 230000002757 inflammatory Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 201000002674 obstructive nephropathy Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 201000004681 psoriasis Diseases 0.000 claims description 4
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 201000006704 ulcerative colitis Diseases 0.000 claims description 4
- 108009000283 Allograft Rejection Proteins 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 208000010247 Contact Dermatitis Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims description 3
- 210000001508 Eye Anatomy 0.000 claims description 3
- 206010051040 Hyper IgE syndrome Diseases 0.000 claims description 3
- 208000009388 Job Syndrome Diseases 0.000 claims description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 231100000080 dermatitis contact Toxicity 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- CMGVHADRUHRDHV-UHFFFAOYSA-N 2-(3-butylsulfonyl-5-fluoro-2-methylindol-1-yl)acetic acid Chemical compound C1=C(F)C=C2C(S(=O)(=O)CCCC)=C(C)N(CC(O)=O)C2=C1 CMGVHADRUHRDHV-UHFFFAOYSA-N 0.000 claims description 2
- IMYHCQOFSFUUDK-UHFFFAOYSA-N 2-(5-fluoro-2-methyl-3-quinolin-8-ylsulfonylindol-1-yl)acetic acid Chemical compound C1=CN=C2C(S(=O)(=O)C3=C(N(C4=CC=C(F)C=C43)CC(O)=O)C)=CC=CC2=C1 IMYHCQOFSFUUDK-UHFFFAOYSA-N 0.000 claims description 2
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 claims description 2
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 claims description 2
- 229960005475 Antiinfectives Drugs 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960004675 Fusidic Acid Drugs 0.000 claims description 2
- IECPWNUMDGFDKC-MZJAQBGESA-N Fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 229960003088 Loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- 108010029597 Omalizumab Proteins 0.000 claims description 2
- 229960000470 Omalizumab Drugs 0.000 claims description 2
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 claims description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
- 208000006641 Skin Disease Diseases 0.000 claims description 2
- 101710040537 TNF Proteins 0.000 claims description 2
- 229960001967 Tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 108010049535 anti-IgE antibodies Proteins 0.000 claims description 2
- 230000000843 anti-fungal Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000002924 anti-infective Effects 0.000 claims description 2
- 229940121375 antifungals Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000000903 blocking Effects 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 2
- 229960000060 monoclonal antibodies Drugs 0.000 claims description 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- 229960004017 salmeterol Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 2
- 229960005332 zileuton Drugs 0.000 claims description 2
- 102100020039 HPGDS Human genes 0.000 claims 4
- 101700056286 HPGDS Proteins 0.000 claims 4
- 101710005265 pgdP Proteins 0.000 claims 4
- 102100007288 PTGDR2 Human genes 0.000 claims 3
- 101710013017 PTGDR2 Proteins 0.000 claims 3
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 4
- 150000004677 hydrates Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cells Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 125000006519 CCH3 Chemical group 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 125000001041 indolyl group Chemical group 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000002194 synthesizing Effects 0.000 description 6
- 101700067048 CDC13 Proteins 0.000 description 5
- 210000003979 Eosinophils Anatomy 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 102000003938 Thromboxane Receptors Human genes 0.000 description 5
- 108090000300 Thromboxane Receptors Proteins 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229960000905 Indomethacin Drugs 0.000 description 4
- 229960004793 Sucrose Drugs 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Chemical class 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003495 polar organic solvent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- INCDUEBSCYZGDW-UHFFFAOYSA-N 2-[3-[(4-chlorophenyl)sulfamoyl]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NC1=CC=C(Cl)C=C1 INCDUEBSCYZGDW-UHFFFAOYSA-N 0.000 description 3
- BULFKQNIZODZDC-UHFFFAOYSA-N 3-sulfonylindole Chemical class C1=CC=C2C(=S(=O)=O)C=NC2=C1 BULFKQNIZODZDC-UHFFFAOYSA-N 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 229940014259 Gelatin Drugs 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002327 eosinophilic Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000011630 iodine Chemical group 0.000 description 3
- 229910052740 iodine Chemical group 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ICZYASKCTFUTHY-UHFFFAOYSA-N 2-[3-(1,3-benzothiazol-2-ylsulfanyl)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1SC1=NC2=CC=CC=C2S1 ICZYASKCTFUTHY-UHFFFAOYSA-N 0.000 description 2
- VXNKRNKINWBGHK-UHFFFAOYSA-N 2-[3-(2-amino-2-oxoethyl)sulfonyl-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound FC1=CC=C2N(CC(O)=O)C(C)=C(S(=O)(=O)CC(N)=O)C2=C1 VXNKRNKINWBGHK-UHFFFAOYSA-N 0.000 description 2
- WSSRRZNRGIEBEY-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(2-methylsulfonylethylsulfonyl)indol-1-yl]acetic acid Chemical compound FC1=CC=C2N(CC(O)=O)C(C)=C(S(=O)(=O)CCS(C)(=O)=O)C2=C1 WSSRRZNRGIEBEY-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 210000003651 Basophils Anatomy 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000000172 allergic Effects 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atoms Chemical class N* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- HVAHYVDBVDILBL-UHFFFAOYSA-M potassium;oxidooxy hydrogen sulfate Chemical compound [K+].OS(=O)(=O)OO[O-] HVAHYVDBVDILBL-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VSRXYLYXIXYEST-KZTWKYQFSA-N 13,14-Dihydro-15-keto-PGD2 Chemical compound CCCCCC(=O)CC[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O VSRXYLYXIXYEST-KZTWKYQFSA-N 0.000 description 1
- AKSKDJAFNCAVPW-UHFFFAOYSA-N 1H-indole-3-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)=CNC2=C1 AKSKDJAFNCAVPW-UHFFFAOYSA-N 0.000 description 1
- OPXIANWZZLIHLY-UHFFFAOYSA-N 2-[3-(1,3-benzothiazol-2-ylsulfonyl)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C1=CC=C2SC(S(=O)(=O)C3=C(N(C4=CC=C(F)C=C43)CC(O)=O)C)=NC2=C1 OPXIANWZZLIHLY-UHFFFAOYSA-N 0.000 description 1
- MLBJYXIZOQAOCT-UHFFFAOYSA-N 2-[3-(benzylsulfamoyl)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NCC1=CC=CC=C1 MLBJYXIZOQAOCT-UHFFFAOYSA-N 0.000 description 1
- QBZKVULXERLJSN-UHFFFAOYSA-N 2-[3-(carboxymethylsulfonyl)-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound FC1=CC=C2N(CC(O)=O)C(C)=C(S(=O)(=O)CC(O)=O)C2=C1 QBZKVULXERLJSN-UHFFFAOYSA-N 0.000 description 1
- NFAOUSAZFFTFJK-UHFFFAOYSA-N 2-[3-[(4-chlorophenyl)methylsulfamoyl]-5-fluoro-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NCC1=CC=C(Cl)C=C1 NFAOUSAZFFTFJK-UHFFFAOYSA-N 0.000 description 1
- VOJJHNHDGRPZFP-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-(pyridin-3-ylsulfamoyl)indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NC1=CC=CN=C1 VOJJHNHDGRPZFP-UHFFFAOYSA-N 0.000 description 1
- KFMXKOTXHJCJNQ-UHFFFAOYSA-N 2-[5-fluoro-2-methyl-3-[(3-methylphenyl)sulfamoyl]indol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NC1=CC=CC(C)=C1 KFMXKOTXHJCJNQ-UHFFFAOYSA-N 0.000 description 1
- YFCHJYREOGXCPR-UHFFFAOYSA-N 2-[5-fluoro-3-[(4-fluorophenyl)sulfamoyl]-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(F)=CC=C2N(CC(O)=O)C(C)=C1S(=O)(=O)NC1=CC=C(F)C=C1 YFCHJYREOGXCPR-UHFFFAOYSA-N 0.000 description 1
- JHIJTKDCAVEEFJ-UHFFFAOYSA-N 2-[5-fluoro-3-[(4-methoxyphenyl)sulfamoyl]-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=C(C)N(CC(O)=O)C2=CC=C(F)C=C12 JHIJTKDCAVEEFJ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YAQLSKVCTLCIIE-UHFFFAOYSA-M 2-bromobutanoate Chemical compound CCC(Br)C([O-])=O YAQLSKVCTLCIIE-UHFFFAOYSA-M 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-Chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-M 4-chlorobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-M 0.000 description 1
- JJIUISYYTFDATN-UHFFFAOYSA-N 5-fluoro-2-methyl-1H-indole Chemical compound FC1=CC=C2NC(C)=CC2=C1 JJIUISYYTFDATN-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- ZIDQIOZJEJFMOH-UHFFFAOYSA-N 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid Chemical compound C1CCCCC1C(O)CCN1C(CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 108060006634 CAMP Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000011652 Formyl Peptide Receptors Human genes 0.000 description 1
- 108010076288 Formyl Peptide Receptors Proteins 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 229940015001 Glycerin Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960001375 Lactose Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100011503 PTGDS Human genes 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229940083542 Sodium Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 210000004241 Th2 Cells Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102200011870 ZNF616 P50S Human genes 0.000 description 1
- GSNYNRHQAWWRGT-UHFFFAOYSA-K [Br-].[In+3].C(CCC)S(=O)(=O)C1=C(NC2=CC=C(C=C12)F)C.[Br-].[Br-] Chemical compound [Br-].[In+3].C(CCC)S(=O)(=O)C1=C(NC2=CC=C(C=C12)F)C.[Br-].[Br-] GSNYNRHQAWWRGT-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- BOIZHGCLUSQNLD-UHFFFAOYSA-N acetic acid;1H-indole Chemical class CC(O)=O.C1=CC=C2NC=CC2=C1 BOIZHGCLUSQNLD-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 229940054051 antipsychotic Indole derivatives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic Effects 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- WEDIIKBPDQQQJU-UHFFFAOYSA-N butane-1-sulfonyl chloride Chemical compound CCCCS(Cl)(=O)=O WEDIIKBPDQQQJU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-M cyclopentanecarboxylate Chemical compound [O-]C(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-M 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XCVUPRULBFEFCC-UHFFFAOYSA-N ethyl 2-(5-fluoro-2-methylindol-1-yl)acetate Chemical compound FC1=CC=C2N(CC(=O)OCC)C(C)=CC2=C1 XCVUPRULBFEFCC-UHFFFAOYSA-N 0.000 description 1
- KZMDADQYUHRSMA-UHFFFAOYSA-N ethyl 2-[3-[(4-chlorophenyl)sulfamoyl]-5-fluoro-2-methylindol-1-yl]acetate Chemical compound C12=CC(F)=CC=C2N(CC(=O)OCC)C(C)=C1S(=O)(=O)NC1=CC=C(Cl)C=C1 KZMDADQYUHRSMA-UHFFFAOYSA-N 0.000 description 1
- KYQOOXPOLJFJCQ-UHFFFAOYSA-N ethyl 2-[5-fluoro-2-methyl-3-(2-methylsulfonylethylsulfonyl)indol-1-yl]acetate Chemical compound FC1=CC=C2N(CC(=O)OCC)C(C)=C(S(=O)(=O)CCS(C)(=O)=O)C2=C1 KYQOOXPOLJFJCQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000006956 minimum essential medium Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 101710035540 plaa2 Proteins 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010047707 prostaglandin R2 D-isomerase Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000003252 repetitive Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical class CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JKNHZOAONLKYQL-UHFFFAOYSA-K tribromoindigane Chemical compound Br[In](Br)Br JKNHZOAONLKYQL-UHFFFAOYSA-K 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
Abstract
Compounds of general formula (I) and their pharmaceutically acceptable salts, hydrates, solvates, complexes and prodrugs are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
Description
COMPOUNDS THAT HAVE CRTH2 ANTAGONIST ACTIVITY
FIELD OF THE INVENTION The present invention relates to compounds that are useful as drugs, to methods for preparing those compounds, compositions containing them and their uses for the treatment and prevention of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis and other Inflammatory diseases mediated by prostaglandin D2 (PGD2) that acts as the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.
BACKGROUND OF THE INVENTION PGD2 is an eicosanoid, a kind of chemical mediator synthesized by cells in response to local tissue damage, normal stimuli or hormonal stimuli or by cellular activation pathways. Eicosanoids bind to specific cell surface receptors on a wide variety of tissues throughout the body and mediate various effects on those tissues. It is known that PGD2 is produced by mast cells, macrophages and Th2 lymphocytes and has been detected in high concentrations in the airways of asthmatic patients challenged with antigen (Murray et al, (1986), N. Engl.
J. Med. 315: 800-804). The instillation of PGD2 in the airways can cause many characteristics of the asthmatic response, including bronchoconstriction (Hardy et al, (1984) N. Engl. J. Med. 311: 209-213; Sampson et al., (1997) Thorax 52: 513-518) and accumulation of eosinophils (Ery et al, (1989) J. Appl. Physiol. 67: 959-962). The potential of PGD2 applied exogenously to induce inflammatory responses has been confirmed by the use of transgenic mice that overexpress human PGD2 synthase which exhibit exaggerated eosinophilic pulmonary inflammation and Th2 cytokine production in response to antigen (Fujitani et al, (2002 J. Immunol. 168: 443-449). The first specific receptor for PGD2 when discovered was the DP receptor which is linked to the elevation of intracellular levels of cAMP. However, it is thought that PGD2 mediates much of its proinflammatory activity through interaction with a G-protein coupled receptor called CRTH2 (molecule homologous to the chemoattractant receptor expressed on Th2 cells) which is expressed by Th2, eosinophilic lymphocytes. and basophils (Hirai et al, (2001) J. Exp. Med. 193: 255-261, and EP0851030 and EP-A-1211513 and Bauer et al, EP-A-1170594). It seems to be clear that the effect of PGD2 on the activation of Th2 lymphocytes and eosinophils is mediated through CRTH2 since selective CRTH2 agonists 13,14 dihydro-15-keto-PGD2
(DK-PGD2) and 15R-methyl-PGD2 can produce this response and the effects of PGD2 are blocked by an anti-CRTH2 antibody (Hirai et al, 2001; Monneret et al, (2003) J.
Pharmacol. Exp. Ther. 304: 349-355). In contrast, the selective DP agonist of BW245C does not promote the migration of Th2 or eosinophil lymphocytes (Hirai et al, 2001; Gervais et al, (2001) J. Allergy Clin. Immunol., 108: 982-988). On the basis of this evidence, the antagonism of
PGD2 at the CRTH2 receptor is an attractive method to treat the inflammatory component of allergic and Th2-dependent diseases such as asthma, allergic rhinitis and atopic dermatitis. EP-A-1170594 suggests that the method with which it is related can be used to identify compounds that are of use in the treatment of allergic asthma, atopic dermatitis, allergic rhinitis, autoimmune disease, reperfusion injury and a number of inflammatory conditions. , all of which are mediated by the action of PGD2 on the CRTH2 receiver. Compounds that bind to CRTH2 are taught in WO-A-03066046 and WO-A-03066047. These compounds are not novel but were described for the first time, together with similar compounds, in GB 1356834, GB 1407658 and GB 1460348, where they are said to have anti-inflammatory, analgesic and antipyretic activity. WO-A-03066046 and WO-A-03066047 teach that the compounds in which they are related are modulators of CRTH2 receptor activity and therefore are of use in the treatment or prevention of obstructive airway diseases such as asthma, chronic obstructive pulmonary disease (COPD) and a number of other diseases including various conditions of the bones and joints, skin and eyes, Gl tract, central and peripheral nervous system and other tissues as well as the rejection of an allograft. The compounds described in those documents are indoles with a carboxylic acid group being in the 3-position of the system of an indole ring, a quinoline, quinazoline or benzothiazole group in the 1-position.
SUMMARY OF THE INVENTION The present invention relates to novel compounds which bind to CRTH2 and which will therefore also be useful in the treatment of diseases and conditions mediated by the activity of PGD2 at the CRTH2 receptor. In the present invention, compounds of general formula (I) are provided
where R1, R2, R3 and R4 are independently hydrogen, halo, C6-C6 alkyl, -O (C6-C6 alkyl), -CON (R9) 2, -SOR9, -S02R9, -S02N (R9) 2, -N (R9) 2, -NR9COR9, -C02R9, -COR9, -SR9, -OH, -N02 or -CN; each R5 is independently hydrogen or C-Ce alkyl; R 5 and R 6 are each independently hydrogen, or C 1 -C 6 alkyl or together with the carbon atom which is attached form a C 3 -C 7 cycloalkyl group; R is hydrogen or C? -C6 alkyl is 1 or 2; X is a bond or, when n is 2, X may also be a group NR9; where R9 is as defined above; when X is a bond R8 is a C-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, biphenyl or a bicyclic or tricyclic heteroaryl group of 9-14 members; when X is a group NR9 and R8 can additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and The R8 group is optionally substituted with one or more substituents selected from halo, C? -C6 alkyl, -0 (C? -C6) alkyl, aryl, -O-aryl, heteroaryl, -O-heteroaryl, -CON (R9) 2, -SOR9, -S02R9, S02N (R9) 2, -N (R9) 2, -NR9COR9, -C02R9, -COR9, -SR9, -OH, -N02-CN; where R9 is as defined above; or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof Compounds of general formula (I) are antagonists of PGD2 at the CRTH2 receptor and will therefore be useful in the treatment of conditions that are mediated by the binding of PGD2 to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases, examples of which are allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis and contact hypersensitivity, (including contact dermatitis) conjunctivitis, or especially allergic conjunctivitis, bronchitis eosinophilic, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other diseases mediated by PGD2, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematosus, psoriasis, acne, sclerosis multiple, graft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Similarly, but not identical, the compounds are described in WO-A-9950268. These compounds differ from those of the present invention in that they do not contain a sulfone / sulfonamide moiety attached at the 3-position of the indole ring. In addition, it is not taught that they are useful in the treatment of conditions such as asthma and allergic conditions, which are mediated by PGD2. In addition, in the treatment of complications arising from diabetes mellitus. PL 65781 and JP 43-24418 are also related to indole derivatives. However, the compounds described in both of these documents differ from the compounds of the present application in that they are indole N-sulfonamides in place of 3-sulfones or 3-sulfonamides as the compounds of the present invention. The compounds described in PL 65781 and JP 43-24418 are similar in structure to indomethacin, and like indomethacin are said to have anti-inflammatory and antipyretic activity. Thus, although this may not have been appreciated at the time when those documents were the compounds they describe are COX inhibitors, an activity that is very different from the compounds of the present invention. In fact, COX inhibitors are contraindicated in the treatment of many diseases and conditions, for example asthma, and inflammatory bowel disease, for which the compounds of the present invention are useful, although they can sometimes be used to treat arthritic conditions. Compounds that bind to the CRTH2 receptor are described in WO-A-03/097042 and WO-A-03/097598. These compounds are indole acetic acids but in WO-A-03/097042 the indole system is fused at positions 2-3 to a 5-7 membered carbocyclic ring. In WO-A-03/097598 there is a pyrrolidine p in the 3-position of the indole. WO-A-03/101981 and WO-A-03/101961 both relate to the CRTH2 antagonist. The compounds described in WO-A-03/101961 are similar to the structure of the compounds of the present invention in which X is a bond. They differ from the compounds of the general formula (I) because there is a p -S- linked to the 3-position of the indole instead of the SO or S02 p of the compounds of the general formula (I). In addition, the p equivalent to the p R8 in the compounds of general formula (I) is an aryl or heteroaryl p. There are no aliphatic substituents in this position, as with the compounds of general formula (I). It has surprisingly been found that although these compounds have a high intrinsic activity, they are less suitable for use as medicaments in the compounds of the present invention. This is because certain of the compounds of WO-A-03/101961 are inhibitors of cytochrome P50S and thus have implications for the metabolism of any pharmacological agent that can be co-administered with those compounds. In contrast, the inventors of the present have shown that, surprisingly, the compounds of the present invention do not inhibit cytochrome PsoS. In addition, our preliminary binding experiments have indicated that the sulfide compounds described in WO-A-03/101961 appear to bind to human eosinophils at a low speed, which could lead to an unappreciated duration of action. WO-A-03/10981 relates to compounds that are similar in structure to the compounds of the present invention, except that the substituent in the 3-position of the indole ring system is a phenyl, naphthyl or heteroaryl p without a linker. of SO, S02 or S02NR9, with the compounds of general formula (I). Clearly the inclusion of the linking p probably has a substantial effect on the activity of the compound. In addition, the substituent in the 3- position of the indole can not be an aliphatic p, as in the present invention. WO-A-2004/007451 relates to inhibitors of CRTH2 which are similar in structure to the compounds of the present invention in which X is a bond, except that the p equivalent to the p R8 of the compounds of formula general (I) is a 5-7 membered phenyl, naphthyl or heteroaromatic p. In effect, all the exemplified compounds have a substituted phenyl p in this position. This is clearly different from the compounds of the present invention where the R8 ps are a bicyclic or tricyclic heteroaromatic ring, or an alkyl, alkenyl or alkynyl p. It is particularly surprising that the compounds containing alkyl, alkenyl and alkynyl ps have proven to be active since they differ markedly in the structure of the prior art compounds. In the present specification "C? -C6 alkyl" refers to a straight or branched saturated hydrocarbon chain having one to six carbon atoms and optionally substituted with one or more halo substituents, or with one or more C3 cycloalkyl ps -C. Examples include methyl, ethyl, n-propyl, isopropyl, t-butyl, n-hexyl, trifluoromethyl, 2-chloroethyl, methylenecyclopropyl, ethylenecyclobutyl, methylenecyclobutyl and methylenecyclopentyl. "C-C alkyl" and "C-C18 alkyl" have similar meaning except that they contain more than one to four and one to eighteen carbon atoms respectively. C3-C-cycloalkyl refers to a 3 to 7 membered saturated carbocyclic ring. Examples of those ps include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The terms "C2-C6 alkenyl,!" And "C2-C6 alkynyl" refer to straight or branched hydrocarbon chains having from two to six carbon atoms containing respectively at least one carbon-carbon double bond or at least one a carbon-carbon triple bond As with alkyl groups, they may be optionally substituted with one or more halo substituents or with one or more C3-C7 cycloalkyl groups In the present specification, "halo" refers to fluorine, chlorine , bromine or iodine The terms "aromatic portion" and "aryl" in the context of the present specification refer to an aromatic ring system having from 5 to 14 carbon atoms in the ring and containing up to three rings. of aromatic moieties are benzene and naphthalene.The aryl groups may be substituted with one or more substituents selected from halo, C? -C? alkyl ?, C? -C6 alkoxy, a 5-7-membered heterocyclic ring or S02R9 where R9 is as defined above. The terms "heteroaromatic portion" and "heteroaryl" refer to an aromatic ring system in which at least one of the ring carbon atoms is replaced by a nitrogen, oxygen or sulfur atom. Examples include simple ring systems such as pyridine, pyrimidine, pyrazole, thiophene, oxazole and isoxazole. Other examples include fused ring systems such as quinoline, isoquinoline, quinazoline, benzothiazole, benzoxazole, benzimidazole and indole groups. Unless otherwise stated a heteroaromatic portion has 5 to 14 carbon atoms in the ring, but, for example, the "5- to 7-membered heteroaromatic ring" contains from 5 to 7 ring atoms. The bicyclic and tricyclic heteroaryl groups contain respectively two to three fused rings. The bicyclic heteroaryl groups can be, for example, ring systems 6,6- or 6-5- those exemplified above. As with the aryl groups, the heteroaryl groups can also be substituted with one or more substituents chosen from halo, C? -C6 alkyl, C-C6 alkoxy, a 5-7-membered heterocyclic ring or S02R9 where R9 is as It was defined earlier. The term "5- to 7-membered heterocyclic ring" refers to a non-aromatic ring system having from 5 to 7 ring atoms and where at least one of the ring carbon atoms is replaced by a nitrogen atom, oxygen or sulfur. Examples include piperidine, morpholine, imidazole, piperazine and tetrahydrofuran. Appropriate pharmaceutically and veterinarily acceptable salts of the compounds of general formulas (I) and (II) include basic addition salts such as the sodium, potassium, calcium, aluminum, zinc, magnesium and other metal salts as well as choline, diethanolamine, ethanolamine , ethyl diamine and other well-known basic addition salts. Where appropriate, pharmaceutically or veterinarily acceptable salts may also include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate , benzoate, butyrate, digluconate, cyclopentanate, gluco-heptane, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, pamoate, pectinate, 3-phenylpropionate, picrate, pivalate, propionate, tartrate, lactobionate, pivolate, camphorrate, undecanoate and succinate , organic sulphonic acids such as methanesulfonate, ethanesulfonate, 2-hydroxyethane sulfonate, camphorsulfonate, 2-naphthalene sulfonate, benzenesulfonate, p-chlorobenzenesulfonate and p-toluenesulfonate; and inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfate, bisulfate, hemisulfate, thiocyanate, persulfate, phosphoric and sulphonic acids. Salts that are not pharmaceutically or veterinarily acceptable can still be valuable as intermediates. Prodrugs are any covalently linked compounds that release the active parent drug according to general formula (I) in vivo. Examples of prodrugs include the alkyl esters of the compounds of general formula (I), for example the esters of the general formula (II) below. If a chiral center or other isomeric center form is present in a compound of the present invention, all forms of that isomer or isomers, including the enantiomers and diastereomers, are intended to be covered here. The compounds of the invention which contain a chiral center can be used as a racemic mixture, a mixture enriched above, or the racemic mixture can be separated using well known techniques and an individual enantiomer can be used alone. The compounds of general formula (I), it is preferred that, independently or in any combination: R1 is halo or hydrogen; R2 is halo or hydrogen; R3 is halo or hydrogen; R4 is halo or hydrogen; In more preferred compounds, R1, R3 and R4 are hydrogen, while R2 is also halo, particularly fluorine. In preferred compounds of general formula (I), R5 and R6 are each independently hydrogen or C? -C4 alkyl. However, in more active compounds, at least one, and preferably both of R5 and R6 are hydrogen. The compounds of general formula (I) preferably have a group R7 selected from H or C? -C6 alkyl; more adequately R7 is methyl. In particularly preferred compounds of general formula (I), n is 2. When X is a bond, it is preferred that R 8 is C 1 -C 6 alkyl, biphenyl or a bicyclic heteroaryl group or any of which may be substituted by halogen, phenyl, -C02R9 CON (R9) 2 or -S02R9, where R9 is as defined above. The most preferred compounds in which X is a bond include those in which Rs is an alkyl group of C? -C, biphenyl or a bicyclic heteroaryl, any of which may be substituted with phenyl, -C02R9 CON (R9) 2 or -S02R9, where R9 is H or C? -C4 alkyl. When X is NR9, it is preferred that R9 is H or methyl and R8 is: phenyl optionally substituted with one or more halo groups, C-C6 alkyl or -O (C? -C6 alkyl) C? -C6 alkyl, optionally substituted with aryl; or heteroaryl. More preferably, when X is NR9, R8 is phenyl, benzyl or pyridyl, any of which may be optionally substituted with one or more halo, methyl or methoxy groups. Among the most preferred compounds are the following: 1. [3- (Butan-1-sulfonyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. 2. Acid 3 (biphenyl-4-sulfonyl) ) -5-fluoro-2-methyl-indol-1-yl] -acetic acid 3. (3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid 4. Acid (3- Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid 5. [5-Fluoro-3- (2-methanesulfonyl-ethansulfonyl) -2-methyl-indol-1-yl] -acetic acid 6. [3- (Benzothiazole-2-sulfonyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. 7. [3- (Benzothiazol-2-sulfinyl) -5-fluoro-2- acid. methyl-indole-1-yl] -acetic acid. 8. [5-Fluoro-2-methyl-3- (quinolin-2-sulfo-nyl) -indol-1-yl] -acetic acid. Acid [5-Fluoro- 2-methyl-3- (quinolin-8-yl-sulfonyl) -indol-1-yl] -acetic acid 10. (5-Fluoro-2-methyl-3-phenylmetansulfo-nyl-lH-indol-1-yl) -acetic 11. [3- (4-Chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. [3- (3-Chloro-phenylsulfamoyl) -5-fluoro- 2-methyl-indol-l-il] -acé 13. Acid [3- (4-Fluoro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. [3- (2-Chloro-phenylsulfamoyl) -5-fluoro-2 acid] -methyl-indol-1-yl] -acetic acid 15. (3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid. Acid [5-Fluoro-3- (2-methoxy) phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid. [5-Fluoro-3- (4-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid. -Fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl) -acetic acid 19. [3- (3,4-Dichloro-benzylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] - acid Acetic acid 20. [5-Fluoro-3- (3-methoxy-phenylsulfamoyl)]
-2-methyl-indole-l-yl] -acetic acid 21. Acid (5-Fluoro-2-methyl-3-m-tolylsulfamoyl-indol-1-yl) -acetic acid. 22. Acid (5-Fluoro-2-methyl) -3-p-tolylsulfamoyl-indol-1-yl) -acetic acid 23. [3- (4-Chloro-benzylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. Acid [3] - (Benzyl-methyl-sulfamoyl) -5-fluoro-2-methyl-indole-1-yl] -acetic acid. Acid [5-Fluoro-2-methyl-3- (pyridin-3-yl-sulfamoyl) -indole -1-yl] -acetic; or the alkyl esters of C? -C6, aryl, (CH2) mOC (= 0) -alkyl of C? -C6, (CH2) mN (R11) 2, CH ((CH2) mO (C = 0) R12 2 of any of the above; where m is 1 or 2; R11 is hydrogen or methyl; R12 is C? -C? 8 alkyl. In a further aspect of the present invention, a compound of general formula (II) is provided:
where R1, R2, R3, R4, R5, R6, n, X, R7 and R8 are as defined for the general formula (I); R10 is C? -C6 alkyl, aryl, (CH2) m0C (= 0) C? -C6 alkyl,
CH2) mN (R >? A ??) 2, CH ((CH2) mO (C = 0) R 1 ± 2 ?,) 2; m is 1 or 2; R11 is hydrogen or methyl; R12 is C? -C? Alkyl. The compounds of general formula (II) are novel and can be used as prodrugs for compounds of general formula (I). When the compound of general formula (II) acts as a prodrug, the latter is converted to drug by the action of an esterase in the blood or tissue of the patient. Examples of particularly suitable R10 groups when the compound of general formula (II) is used as a prodrug includes: methyl, ethyl, propyl, phenyl, CH20C (= 0) tBu, CH2CH2N (Me) 2 CH2CH2NH2 or CH (CH20 (C = 0) R12) 2 where R12 is as defined above. The compounds of general formula (I) wherein R 1,
R2, R3, R4, R5, R6, R7 and R8 are as defined for the general formula (I) and X is a bond, they can be prepared from compounds of the general formula
(la), which is a compound of general formula (I) wherein n is 0 and X is a bond by oxidation with a suitable oxidizing agent such as potassium peroxymonosulfate, m-CPBA, hydrogen peroxide or other well-known oxidizing reagents. In addition to their use as prodrugs, the compounds of general formula (II) wherein R 10 is alkyl
C1-C6 can be used in a process for the preparation of a compound of general formula (I), the process comprising reacting the compound of general formula (II) with a base such as sodium hydroxide or lithium hydroxide. The reaction can take place in an aqueous solvent or an organic solvent or a mixture of the two. A typical solvent used for the reaction is a mixture of tetrahydrofuran and water. The same method can be used to prepare compound of general formula (la) as defined above from the compounds of general formula (lia), which are identical to the compounds of general formula (II) except that n is 0. The compounds of general formula (II) and (lía) in which X is a bond can be prepared from the compounds of general formula (III):
III wherein R1, R2, R3, R4, R7 and R8 are as defined for the general formula (I) and n is O, 1 or 2; by reaction with a compound of general formula (IV): X-CR5R6-C02R10 (IV) wherein R5 and R6 are as defined for general formula (I), R10 is as defined for general formula (II) and X is a leaving group, in particular a halo group, for example bromine. The reaction is conducted under strongly basic conditions, for example in the presence of excess sodium hydride and in a polar organic solvent such as dimethylformamide. The compounds of general formula (IV) are well known and readily available or can be prepared by methods known to those skilled in the art. The compounds of general formula (III) wherein R1, R2, R3, R4, R7 and R8 are as defined for the general formula (I) and n is 2; they can be prepared by reacting a compound of general formula (V):
V where R1, R2, R3, R4, and R7 are as defined in general formula (I); with a compound of general formula (VI): R8-S02C1 (VI) wherein R8 is as defined in general formula (I).
The reaction is carried out in the presence of a Lewis acid such as indium (III) bromide. The reaction can be conducted in a polar organic solvent, particularly a chlorinated solvent such as 1,2-dichloroethane. The compounds of general formulas (V) and (VI) are well known in the art and are readily available or can be prepared by known methods. The compounds of general formula (II) in which X is NR 9 can be prepared from the compounds of general formula (VII):
VII wherein R1, R2, R3, R4, R5, R6 and R7 are as defined for the general formula (I) and R10 is as defined in the general formula (II) by the reaction with a compound of the general formula (VIII ): HNR8R9 (VIII) where R8 and R9 are as defined above for the general formula (I). The reaction solvent can be a polar organic solvent such as dichloromethane. The compounds of general formula (VIII) are well known and readily available or can be prepared by methods well known to those skilled in the art. The compounds of general formula (VII) can be prepared from compounds of general formula (IX)
0
IX wherein R1, R2, R3, R4, R5, R5 and R7 are as defined for the general formula (I) and R10 is as defined for the general formula (II); by reaction with chlorosulfonic acid. The reaction preferably takes place in a non-polar organic solvent. The compounds of general formula (IX) are well known and readily available or can be prepared by methods well known to those skilled in the art. The compounds of general formula (III) wherein Ra, R2, R3, R4, R7, and R8 are as defined for the general formula (I) and n is 0 can be prepared by reacting a compound of general formula (IX) wherein R1 , R2, R3, R4, and R7, are as defined in the general formula (I) and R10 is as defined for the general formula (II); by a compound of general formula (X): R8-SH (X) wherein R8 is as defined in general formula (I). The reaction is carried out in the presence of iodine and potassium iodide. The reaction can take place in an aqueous or organic solvent or a mixture of the two. A typical solvent used for the reaction is a mixture such as ethanol and water. The compounds of the general formula (I) are antagonists of the PGD at the CRTH2 receptor and the compounds of the general formula (II) are prodrugs for the compounds of the general formula (I). The compounds of general formulas (I) and (II) are therefore useful in a method for the treatment of diseases and conditions mediated by PGD2 at the CRTH2 receptor, the method comprises administering to a patient in need of such treatment an amount of a compound of general formula (I) or (II). In a third aspect of the invention, there is provided a compound of general formula (I) or (II) for use in medicine, particularly for use in the treatment or prevention of diseases and conditions mediated by PGD2 at the CRTH2 receptor. In addition, the use of a compound of general formula (I) or (II) in the preparation of an agent for the treatment or prevention of diseases and conditions mediated by PGD2 at the CRTH2 receptor is also provided. As mentioned above, those diseases and conditions include allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis, and conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, Eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other diseases mediated by PGD2, for example, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematosus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, as well as ratoid arthritis, psoriatic arthritis and osteoarthritis. The compounds of general formula (I) or (II) must be formulated in an appropriate form depending on the diseases or conditions that are required to be treated. Therefore, in a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of general formula (I) or (II) together with a pharmaceutical excipient or carrier. Other active materials may also be present, as may be considered appropriate or contemplated for the disease or condition being treated or prevented. The support, or, if more than one, each of the supports, must be acceptable in the sense of being compatible with other ingredients of the formulation and not be harmful to the recipient. Formulations include those suitable for oral, rectal, nasal, bronchial (inhaled), topical (including eye, buccal and sublingual drops) vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and can be prepared by methods well known in the pharmacy technique. The route of administration will depend on the condition to be treated but the preferred compositions are formulated for oral, nasal, bronchial or topical administration. The compositions can be prepared by bringing into association the active agent defined above with the support. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid supports or both, and then if necessary forming the product. The invention extends to methods for preparing a pharmaceutical composition comprising placing a compound of general formula (I) or (II) together or in association with a pharmaceutically or veterinarily acceptable carrier or vehicle. Formulations for oral administration in the present invention can be presented as: discrete units such as capsules, sachets or tablets each of which contain a predetermined amount of the active agent; as a powder or granules; as a solution or suspension of the active agent in an aqueous liquid or a non-cumbersome liquid; or as an oil-in-water liquid emulsion or water-in-oil liquid emulsion; or as a bolus, etc. For compositions for oral administration (e.g., tablets and capsules) the term "acceptable carrier" includes carriers as common excipients e.g. binding agents, e.g., syrup, acacia, gelatin, sorbitol, tragacanth, polyvinyl pyrrolidone (Povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and supports, for example corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as magnesium stearate, sodium stearate, and other metal stearates, glycerol stearate, stearic acid, fluid silicone, talc, waxes, oils, and colloidal silica. Fluidizing agents such as peppermint, glauteria oil, cherry flavor and the like can also be used. It may be desirable to add a coloring agent to make the dosage form easily identifiable. The tablets may also be coated by methods well known in the art. A tablet can be produced by compression or molding, optionally with one or more accessory ingredients. The compressed tablets can be prepared by compressing in a suitable machine the active agent in a free flowing form as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, conservative, surfactant or dispersing agent. The molded tablets can be produced by molding in a suitable machine a mixture of wet pulverized compound with an inert liquid diluent. The tablets may be optionally coated or labeled or they may be formulated to provide a slow or controlled release of the active agent. Other formulations suitable for oral administration include lozenges comprising the active agent in a flavored base, usually sucrose and acacia or tragacanth, lozenges comprising the active agent in an inert base, or gelatin and glycerin, or sucrose and acacia; buccal washes comprising the active agent in a suitable liquid support. For topical application to the skin, the compounds of general formula (I) or (II) can be produced in a cream, ointment, jelly, solution or suspension, etc. The cream or ointment formulations that can be used for the drug are conventional formulations well known in the art, for example, as described in standard pharmacy textbooks such as the British Pharmacopoeia. The compounds of general formula (I) or (II) can be used for the treatment of the respiratory tract by nasal, bronchial or buccal administration of, for example, aerosols or sprays which can disperse the pharmacological active ingredient in the form of a powder or in Drops form a solution or suspension. Pharmaceutical compositions with powder dispersion properties usually contain, in addition, the active ingredient and with a liquid propellant with a boiling point lower than room temperature, and if desired, adjuvants, such as liquid or solid nonionic or anionic surfactants and / or diluents. The pharmaceutical compositions in which the pharmacologically active ingredient is in solution contain, in addition to this a suitable propellant and further, if necessary, an additional solvent and / or stabilizer. Instead of the propellant, compressed air can also be used, making it possible for it to be produced as required by means of a suitable compression and expansion device. Parenteral formulations will generally be sterile. Typically, the compound dose will be from about 0.01 to 100 mg / kg; to maintain the concentration of the drug in the plasma at an effective concentration to inhibit PGD2 at the CRTH2 receptor. The precise amount of the compound of general formula (I) or (II) that is therapeutically effective, and the route by which that compound is best administered, is actually determined by one skilled in the art by comparing the blood level of the agent with the concentration required to have a therapeutic effect. The compounds of general formula (I) or (II) can be used in combination with one or more active agents which are useful in the treatment of the diseases and conditions listed above, although their active agents are not necessarily inhibitors of PGD2 in the CRTH2 receiver. Therefore, the pharmaceutical compositions described above may additionally contain one or more of these active agents. Also provided is the use of a compound of general formula (I) or (II) in the preparation of an agent for the treatment of diseases and conditions mediated by PGD2 at the CRTH2 receptor, wherein the agent also comprises an additional active agent useful for the treatment of the same diseases and conditions. Those additional active agents, which may have a completely different mode of action, include existing therapies for allergic and other inflammatory diseases including: β2 agonists such as salmeterol; corticosteroids such as fluticasone; antihistamines such as loratidine; leukotriene antagonists such as montelukast; therapies with anti-IgE antibody such as omalizumab; anti-infectives such as fusidic acid
(particularly for the treatment of atopic dermatitis); antifungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of inflammatory skin disease. CRTH2 antagonists can also be combined with therapies that are in development for inflammatory indications including: Other PGD antagonists that act in other receptors as DP antagonists; Inhibitors of phosphodiesterase type 4 such as cilonilast; drugs that modulate cytokine production as inhibitors of the TNFa converting enzyme (TACE); drugs that modulate the activity of the Th2 cytokines IL-4 and IL-5 as blocking monoclonal antibodies and soluble receptors; PPAR-agonists and such as rosiglitazone; 5-lipoxygenase inhibitors such as zileuton. In a further aspect of the invention, there is provided a product comprising a compound of general formula (I) or (II) and one or more of the agents listed above as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease or condition mediated by the action of PGD2 at the CRTH2 receptor.
BRIEF DESCRIPTION OF THE FIGURES The invention will now be described in greater detail with reference to the following non-limiting examples and the drawings in which: Figure 1 shows the effect of CRTH2 agonists on calcium mobilization in CHO / CRTH2 cells.
DETAILED DESCRIPTION OF THE INVENTION Example 1- Synthesis of 3-Sulfonyl indole Derivatives (Method A) 1. Synthesis of 3- (Butan-1-sulfonyl) -5-fluoro-2-methyl-1H-indole Indium bromide was added (III) (94.7 mg, 0.267 mmol) in one portion to a solution, with stirring, of 5-fluoro-2-methylindole (50 mg, 0.34 mmol) and butanesulfonyl chloride (418 mg, 2.67 mmol) in 1, 2 -dichloroethane (2 ml) at room temperature. The mixture was subjected to microwave conditions (85 ° C, 150 W) for 45 minutes, cooled to room temperature and then concentrated in vacuo to leave a brown residue. Purification by flash column chromatography on silica gel eluting with 10% ethyl acetate: hexane at 100% ethyl acetate gave the sulfone (55 mg, 15%) as a white off-white solid.
2. Synthesis of [3- (Bt-tan-1-sulfonyl) -5-fluoro-2-methyl-indol-l-yl] -acetic acid Compound 1) 3- (Butan-1-sulfonyl) -5-fluoro was added -2-methyl-lH-indole (55 mg, 0.204 mmol) in DMF (1 ml) was dripped for 1 minute into a suspension, with stirring, of sodium hydride (11 mg, 0.29 mol, 60% in mineral oil) in DMF (1 ml) at 0 ° C. The solution was stirred at 0 ° C for 45 minutes and then ethyl bromoacetate (0.032 ml, 0.29 mmol) was added dropwise and the resulting mixture was stirred at room temperature for 18 hours. The mixture was adjusted to pH 4 with 10% citric acid and then extracted into ethyl acetate (2 x 10 ml). The combined organic extracts were dried and concentrated in vacuo to leave a residue. The residue was extracted THF (1 ml) and then lithium hydroxide monohydrate (19 mg, 0.464 mmol) in water (1 ml) was added in one portion at room temperature. The mixture was stirred at room temperature for 3 hours and then the solution was adjusted to pH 4 with 10% citric acid. The product was extracted with ethyl acetate and the combined organic extracts were dried and concentrated in vacuo to give a residue which was triturated with diethyl ether to give the carboxylic acid as a white off-white solid (5.4 mg, 8%), dH ( 400 MHz,
MeOD) 7.57 (1H, dd J 9.8, 2.3 Hz, Ar), 7.43 (1H, dd J
9. 1, 4.0 Hz, Ar), 7.04 (1H, td J 9.1, 2.5 Hz, Ar), 4.79
(2H, s, CH2C02H), 3.23-3.19 (2H, m, S02CH2), 2.70 (3H, s,
CCH3), 1.77-1.70 (2H, m, CH2CH2CH2CH3), 1.47-1.41 (2H, m, CH2CH2CH2CH3), 0.93 (3H, t J 7.6 Hz, CH2CH2CH2CH3); Tr = 1.38 min, m / z (ES +) (M + H) + 308.24. Tr = 1.82 min (98%), m / z
(ES +) (M + H) + 328.20. Compound 2 was prepared using the same general method as for Compound 1 but with the initial materials chosen appropriately.
Compound 2 2-3- (Biphenyl-4-sulfonyl) -5- fluoro-2-methyl-indol-1-yl] -acetic acid dH (400 MHz, MeOD) 8.03 (2H, d, J 8.6 Hz Ar), 7.80 (2H, d, J 8.6 Hz, Ar), 7.77-7.74 (1H, dd, J 9.6, 2.5Hz, Ar), 7.66-7.64 (2H, dd, J 8.0, 1. 3Hz, Ar), 7.49 -7. 39 (4H, m, Ar), 7.07 (1H, td, J 9.1, 2.5Hz, Ar), 5.07 (2H, s, CH2), 2.76 (3H, s, CH3); Tr = 1.52 min, m / z (ES +) (M + H) + 424.1.
Example 2 - Synthesis of 3-Sulfonyl indole Derivatives (Method B) 1. 2-Methylsulfanyl-ethantiol A solution of methyl iodide (10 ml, 22.82 g, 0.161 mol) in acetone (50 ml) in a suspension was added dropwise. with stirring of etiethiol dithiol (11.24 ml, 12.62 g, 0.134 mol) and potassium carbonate (37.04 g, 0.268 mol) in acetone (150 ml). The resulting mixture was stirred at room temperature for 4 hours. Water (150 ml) was added and the mixture was stirred for an additional 15 minutes. The reaction mixture was extracted with dichloromethane (3 x 200 ml), the organic washes combined, dried over sodium sulphate and evaporated (maintenance pressure above 200 mbar to ensure that there is no coevaporation of the product) to give 2-methylsulfanyl- etantiol The LC / MS showed < 5% initial material and a 2: 1 mixture of mono- and bis-methylated material. The material was used in the following steps without further purification.
2. Ethyl ester of [5-Fluoro-2-methyl-3- (2-methylsulfanyl-ethylsulfanyl) -indol-1-yl] -acetic acid To a stirred solution of ethyl ester of (5-fluoro-2-methyl) acid indol-1-yl) -acetic (1.20g, 5.10 mmol) and 2-methylsulfanyl-ethantiol (1.04g, 6.12mmol) in 1: 1 EtOH: H20 (40ml) at room temperature iodine was added
(1.29g, 5.10mmol) and potassium iodide (0.847g, 5.10 mmol). The mixture was heated to 100 ° C and stirred during
2 hours and then stirred at room temperature for 16 hours. The reaction mixture was quenched by the careful addition of NaHCO3 (aq), then extracted with DCM (2 x 50ml). The organic washes were combined, washed with saturated sodium thiosulfate (2 x 70ml), dried over magnesium sulfate and evaporated to give an oil. The crude oil was purified by chromatography (3 x 12 cm column, 4: 1 hexane: EtOAc as eluent) to give the ester (1.17g, 67%). dH (400 MHz, CDC13) 7.36 (1H, dd J 9.2, 2.5 Hz, Ar), 7.11 (1H, dd J 8.8, 4.1 Hz, Ar), 7.05 (1H, td J 9.2, 2.3 Hz, Ar), 4.79 (2H, s, CH2C02Et), 4.21 (2H, q J 7.2 Hz, C02CH2CH3), 2.86-2.79 (2H, m, CH2CH2), 2.59-2.55 (2H, m, CH2CH2), 2.50 (3H, s, SCH3) , 2.04 (3H, s, CCH3), 1.25 (3H, t J 7.2 Hz, C02CH2CH3).
3. Ethyl ester of [5-Fluoro-3- (2-methanesulfonyl-ethanesulfonyl) -2-methyl-indol-1-yl] -acetic acid. Oxone (8.43 g, 13.7 mmol) was added to a stirred solution of ethyl ester of [5-Fluoro-2-methyl-3- (2-methylsulfanyl-ethylsulfanyl) -indol-1-yl] -acetic acid (1.17g, 3.43mmol) in 4: 1, 4-dioxane: H20 at room temperature. After 30 minutes the reaction mixture was quenched by the careful addition of saturated sodium bicarbonate (50 ml, care for effervescence), then extracted with DCM (2 x 100 ml). The organic washes were combined and washed with brine (2 x lOOml). The aqueous washings were then extracted again with DCM (100 ml). All organic layers were combined, dried over magnesium sulfate and evaporated to give a pale green crystalline solid. The solid was suspended in DCM and collected via filtration to give the ester (l.Oßg, 76%). dH (400 MHz, CDCI3) 7.66
(1H, dd J 9.1, 2.5 Hz, Ar), 7.22 (1H, dd 1 9.0, 4.0 Hz,
Ar), 7.08 (1H, td J 8.9, 2.5 Hz, Ar), 4.86 (2H, s,
CH2C02Et), 4.26 (2H, c J 7.1 Hz, C02CH2CH3), 3.61-3.57 (2H, m, CH2CH2), 3.48-3.44 (2H,, CH2CH2), 2.99 (3H, s, SCH3), 2.71 (3H, s , CH3), 1.30 (3H, t J 7.1 Hz, C02CH2CH3).
4. Compound 5 - [[5-Fluoro-3- (2-mstansulfonyl-ethanesulfonyl) -2-? Tetyl-indol-1-yl] -acetic acid. Lithium hydroxide monohydrate (132 mg, 3.14 mmol) was added in one portion to a solution, with stirring of [5-fluoro-3- (2-methanesulfonyl-ethanesulfonyl) -2-methyl-indol-1-yl] -acetic acid ethyl ester (1.06 g 2.61 mmol) in THF: water (with stirring). 5: 1; 15ml) and the resulting mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo to leave a residue which is partitioned between ethyl acetate and 10% citric acid. The organic layer was separated and the aqueous solution extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were dried and concentrated in vacuo to give a matt white solid. The solid was then triturated with dichloromethane to give the carboxylic acid as a white matte solid, (438 mg, 44%), dH (400 MHz, 6-Acetone) 7.58-7.63 (2H, m, Ar) 7.09 (1H, td J 9.2, 2.6 Hz, Ar), 5.22 (2H, s, CH2C02H), 3.60-3.66 (2H, m, S02CH2CH2), 3.45 (2H, m, S02CH2CH2), 3.02 (3H, s, S02CH3), 2.75 (3H , s, CH3); Tr = 1.08 min (98%), m / z (ES +) (M + H) + 378.16. Compounds 3 and 4 were prepared by a similar route using the appropriate starting materials.
Compound 3 - (3-Carboximetanesulfonyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid Tr = 1.16 min, / z (ES +) (M + H) + 330.10.
Compound 4 (3-Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid Tr = 1.50 min, m / z (ES +) (M + H) + 329.17.
Example 3 - Synthesis of 3-Sulfonyl indole Derivatives (Method B2) A method similar to that set forth in step 2 of Example 2 was used to synthesize the following intermediates. However, hydrolysis to the acid occurred prior to oxidation to give the sulfone or sulfoxide derivative.
[5-Fluoro-2-methyl-3- (quinolin-8-ylsulfa-nyl) -indol-1-yl] -acetic acid dH (400 MHz, MeOD) 8.95-8.94 (1H, m, Ar), 8.36 ( 1H, dd J 8.3, 1.7 Hz, Ar), 7.64-7.60 (2H, m, Ar), 7.45 (1H, dd J 8. 8.4, 2 Hz, Ar), 7.29 (1H, t J 7. 8 Hz, Ar), 7.09 (1H, dd J 9.2, 2.6 Hz, Ar), 7.00 (1H, td J 9.2, 2.6 Hz, Ar), 6.85 (1H, ap d J 7.3 Hz, Ar), 5.14 (2H, s, CH2C02H), 2.52 (3H, s, CCH3); Tr = 1.30 min, m / z (ES +) (M + H) + 367.39.
Acid [5-fluoro-2-methyl-3- (quinolin-2-ylsulphanyl) -indol-1-yl] -acetic dH (400 MHz, MeOD) 8.01 (1H, d J 8.6 Hz, Ar), 7.93 (1H, d J 7.8 Hz, Ar), 7.82 (1H, d J 8.1 Hz, Ar), 7.76 (1H, ap td J 7.1, 1.4 Hz, Ar), 7.53 (1H, ap td J 1 .0, 1.1 Hz, Ar), 7.47 (lH, dd J 9.1, 4.2 Hz, Ar), 7.16 (1H, dd J 9.0, 2.4 Hz, Ar), 7.03 (1H, td J 9.2, 2.6 Hz, Ar), 6.87 (1H , d J 8.8 Hz, Ar), 5.14 (2H, s, CH2C02H), 2.55 (3H, s, CCH3); Tr = 1.37 min, m / z (ES +) (M + H) + 367.24.
[3- (Benzothiazol-2-ylsulfanyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid dH (400 MHz, MeOD) 7.81 (1H d J 8.3 Hz, Ar),
7. 71 (1H, d J 7.8 Hz, Ar), 7.50-7.43 (2H, m, Ar), 7.31-7.24 (2H, m, Ar), 7.06 (1H td J 9.0, 2.4 Hz, Ar), 5.15
(2H, s, CH2C02H), 2.60 (3H, s, CCH3); Tr = 1.49 min, m / z
(ES +) (M + H) + 373.34.
Acid (3-Benzylsulfanyl-5-fluoro-2-methyl-indole-1-yl) -acetic dH (250 MHz, d6-DMSO) 7.46 (1H, dd J 8.8, 4.3 Hz, Ar), 7.21-7.18 (3H , m, Ar), 7.14 (1H, dd J 9.5, 2.5 Hz, Ar), 7.01-6.92 (3H,, Ar), 4.99 (2H, s, CH2C02H), 3.75 (2H, s, ArCH2), 2.01 ( 3H, s, CH3); Tr = 1.56 min (100%) / z (ES +) (M + H) + 330.16. These intermediates can be oxidized to give compounds of general formula (I) where n is 1 or 2 using the following method.
1. Compound 6 - [3- (Benzothiazol-2-sulphonyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid and Compound 7 - [3- (Benzothiazole-2-sulfinyl) -5- acid] -fluoro-2-methyl-indol-1-yl] -acetic Potassium peroxymonosulfate (131.0 mg, 214 mmol) was added in one portion to a solution, with stirring, of [3- (benzothiazol-2-ylsulfanyl) - 5-fluoro-2-methyl-indol-1-yl] -acetic acid (20.0 mg, 53.6 mmol) in 1,4-dioxane: water (0.3 ml, 4: 1) at room temperature. The mixture was stirred at room temperature for 18 h and then a saturated solution of sodium bicarbonate (5 ml) was added. The product was extracted with ethyl acetate (3 ml) and the combined organic extracts were washed with brine and dried in vacuo to leave a residue which was purified with a preparative CLAP to give the sulfone, compound 6.
(10.0 mg, 46%) as a dull white solid, dH (400 MHz,
MeOD) 8.11 (2H, obs dd J 7.9, 2.8 Hz, Ar), 7.79 (1H, dd J
9. 6, 2.5 Hz, Ar), 7.65-7.57 (2H, m, Ar), 7.43 (1H, dd J 8.8, 4.3 Hz, Ar), 7.06 (lH, td J 9.1, 2.5 Hz, Ar), 4.76 (2H , s, CH2C02H), 2.85 (3H, s, CCH3); Tr = 1.44 min (100%), m / z (ES +) (M + H) + 405.21, and the sulfoxide, Compound 7 (3.2 mg, 15%) as a dull white solid, dH (400 MHz, MeOD) 8.16 (1H, ap d J 9.1 Hz, Ar), 8.01 (1H, d J 8.1 Hz, Ar), 7.62-7.54 (2H, m, Ar), 7.47 (1H, dd J 9. 1.4 .0 Hz, Ar), 7.23 (1H, dd J 9. 6.2, 5 Hz, Ar), 7.02 (1H, td J 9.1, 2.0 Hz, Ar), 5.10 (2H, s, CH2C02H), 2.78 (3H, s, CCH3); Tr = 1.34 min (100%), m / z (ES +) (M + H) + 389.09. Compounds 8 to 10 were prepared using the same general method as for compounds 6 and 7, but with the initial materials chosen appropriately.
Compound 8 - [5-Fluoro-2-methyl-3- (quino-lin-2-sulfonyl) -indol-1-yl] -acetic acid dH (400 MHz, MeOD) 8.57 (1H, d J 8.6 Hz, Ar ),
8. 20 (1H, d J 8.6 Hz, Ar), 8.13 (1H, d J 8.6 Hz, Ar), 8.02 (1H, d J 8.1 Hz, Ar), 7.89-7.82 (2H, m, Ar), 7.73 (1H , ap t J 8.1 Hz, Ar), 7.42 (1H, dd J 8.8, 4.3 Hz, Ar), 7.05 (1H, td J 9.1, 2.5 Hz, Ar), 5.08 (2H, s, CH2C02H), 2.86 (3H , s, CCH3); Tr = 1.39 min (92%), m / z (ES +) (M + H) + 399.26. Compound 9 - [5-Fluoro-2-methyl-3- (quinolin-8-ylsulfonyl) -indol-1-yl] -acetic acid dH (400 MHz, MeOD) 8.89 (1H, ap d J 4.3 Hz, Ar), 8.71 (1H, dd J 7.3 Hz, Ar), 8.34 (1H, ap d J 8.3 Hz, Ar), 8.20 (1H, ap d J 8.3 Hz, Ar), 7.80 (1H, t J 8.1 Hz, Ar), 7.58 (1H, dd J 10.1, 2.5 Hz, Ar), 7.53 (1H, dd J 8.3, 4.3 Hz, Ar), 7.34 (1H, dd J 8.8, 4.3 Hz, Ar), 6.95 (1H, td J 9.1, 2.5 Hz, Ar), 5.02 (2H, s, CH2C02H), 2.97 (3H, s, CCH3); Tr = 1.78 min (100%), m / z (ES +) (M + H) + 399.29.
Compound 10 - (5-Fluoro-2-methyl-3-phenyl-methanesulfonyl-1H-indol-1-yl) -acetic acid dH (250 MHz, d6-DMSO) 7.61 (1H, dd J.9.0, 4.5
Hz, Ar), 7.35 (1H, dd J 9.8, 2.5 Hz, Ar), 7.30-7.19 (3H, m, Ar), 7.10 (1H, td J 9.1, 2.6 Hz, Ar), 7.02 (2H, m, Ar), 5.10 (2H, s, CH2C02H), 4.51 (2H, s, ArCH2), 2.06 (3H, s, CH3); Tr = 1.30min (100%) m / z (ES +) (M + H) + 362.13.
Example 4 - Synthesis of 3-Sulfamoyl indole Derivatives (Method C) The method described below is employed for compounds of general formula (I) in which X is NR9.
1. [3- (4-chloro-phenyl-sulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid ethyl ester. Chlorosulphonic acid (0.042 ml, 0.63 mmol) was added dropwise over 1 min. solution, with stirring of (5-fluoro-2-methyl-indol-1-yl) -acetic acid ethyl ester (100 mg, 0.43 mmol) in ether (1 ml) at 0 ° C. The solution was stirred at 0 ° C for 10 min and then concentrated in vacuo to leave a residue which was azeotroped with dichloromethane (2 x 2 ml). The residue was extracted with dichloromethane and then N, N-diisopropyl ethylamine (0.075 ml, 0.43 mmol) and 4-chloroaniline (53.4 mg, 0.42 mmol) were added. The resulting mixture was stirred at room temperature for 40 min. and then concentrated in vacuo to leave the residue which was partitioned between ethyl acetate (5 ml) and water (5 ml). the organic layer was then separated, washed with saturated sodium hydroxide solution (20 ml), dried and concentrated in vacuo to leave a residue which was purified by flash column chromatography (Flashmaster) on silica gel eluting with ethyl acetate at 15%: heptane to give the sulfonamide (6 mg, 3%) as a white matte solid, dH (400 MHz, CDC13) 7.63 (1H, dd J 9.5, 2.4 Hz, Ar), 7.18-7.12 (3H, m , Ar), 7.05-6.99 (1H, m, Ar), 6.96-6.90 (2H, m, Ar), 6.55 (1H, s, NH), 4.73 (2H, s, NCH2), 4.20 (2H, qJ 7.3 Hz, 0CH2CH3), 2.33 (3H, s, CCH3), 1.22 (3H, t J 7.3 Hz, OCH2CH3); Tr = 1.57 min (100%), m / z (ES +) (M + H) + 425.
2. Compound 11-Acid [3- (4-Chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. Lithium hydroxide monohydrate (7.0 mg, 0.17 mmol) in water (2 ml. ) in one portion with a stirring solution of ethyl ester in [3- (4-chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid (6 mg, 0.014 mmol) in tetrahydrofuran (2 ml). The resulting mixture was stirred at room temperature for 3 h and then the pH 1 of the mixture was adjusted with 1M hydrochloric acid. The product extracted with ethyl acetate (2 x 10 ml) and the combined organic extracts were then dried and concentrated in vacuo to give the carboxylic acid (4.3 mg, 77%) as a white off-white solid, dH (400 MHz, CDCl 3). 8.74 (1H, s, NH), 7.70 (1H, dd J 9.5, 2.6 Hz, Ar), 7.13-7.06 (3H,, Ar), 6.99-6.92 (3H, m, Ar), 4.67 (2H, s, NCH2), 2.41 (3H, s, CH3); Tr = 1.84 min (91%), m / z (ES +) (M + H) + 397. Compounds 12 to 25 were prepared using the same general method but with the initial materials chosen appropriately. Compound 12-Acid [3- (3-chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic dH (400 MHz, CDC13) 7.63 (1H, dd J 9.3, 2. 6 Hz , Ar), 7.17-7.14 (1H, m, Ar), 7.10-6.98 (5H, m, Ar, NH), 6.86-6.84 (1H, m, Ar), 4.73 (2H, s, NCH2), 2.46 ( 3H, s, CH3); Tr = 1.84 min (100%), m / z (ES +) (M + H) + 397.
Compound 13-Acid [3- (4-Fluoro-phenylsulfamoyl) -5-luoro-2-methyl-indol-1-yl] -acetic dH (400 MHz, CDC13) 8.45 (1H, s, NH), 7.66 (1H , dd J 9.7, 2.3Hz, Ar), 7.11 (1H, dd J 9.4.2Hz, Ar), 6.97-6.90 (3H, m, Ar), 6.81-6.77 (2H, m, Ar), 4.64 ( 2H, s,
NCH2), 2.29 (3H, s, CH3); Tr = 1.79 min (99%), m / z (ES +)
(M + H) + 381. Compound 14-[3- (2-Chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid dH (400 MHz, CDC13) 7.69 (1H, s, NH), 7.58-7.49
(2H, m, Ar), 7.23-7.13 (3H, m, Ar), 7.03-6.93 (2H, m,
Ar), 4.70 (2H, s, NCH2), 2.44 (3H, s, CH3); Tr = 1.83 (100
%), m / z (ES +) (M + H) + 397. Compound 15-Acid (3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl) -acetic dH (400 MHz, dg-DMSO ) 7.99 (1H, t J 6.3 Hz, Ar),
7. 58 (2H, m, Ar), 7.21 (4H, m, Ar), 7.09 (1H, td J 9.23,
2. 65 Hz, Ar), 5.11 (2H, s, CH2C02H), 3.92 (2H, d J 6.31
Hz, NCH2) 2. 56 (3H, s, CH3), Tr = 1.31min (100%), m / z (ES +) (M + H) + 377. 25 Compound 16-Acid [5-Fluoro-3- (2-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic dH (400 MHz, de-DMSO) 9.18 (1H, s, S02NH), 7.52 (1H, dd J 9.00, 4.4 Hz, Ar), 7.47 (1H, dd J 10.2, 2.6 Hz, Ar), 7.23 (1H, dd J 7.9, 1.6 Hz, Ar), 7.09-7.01 (2H, m,? r), 6.84 (1H, t J 7.7 Hz, Ar), 6.77 (1H, d J 7. 2 Hz, Ar), 5.05 (2H, s, CH2C02H), 3.24 (3H, OCH3), 2.30 (3H, s , CH3); Tr = 1.31 min (100%), m / z (ES +) (M + H) + 393.25. Compound 17-Acid [5-fluoro-3- (4-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic dH (400 MHz, de-DMSO) 9.62 (1H, s, S02NH), 7.49
(1H, dd J 10.3, 2.6 Hz, Ar), 7.36 (1H, dd J 9.0, 4.6 Hz,
Ar), 6.98 (1H, dd J 9.2, 2.8 Hz, Ar), 6.93 (2H, d J 9.1 Hz, Ar), 6.74 (2H, d J 9.1 Hz, Ar), 4.45 (2H, s, CH2C02H),
3. 64 (3H, s, 0CH3), 2.36 (3H, s, CH3); Tr = 1.27 min
(100%), m / z (ES +) (M + H) + 393.26. Compound 18-Acid (5-fluoro-2-methyl-3-enylsulfamido-indol-1-yl) -acetic dH (400 MHz, d6-DMS0) 10.15 (1H, s, S02NH), 7.60
(1H, dd J 10.1, 2.6 Hz, Ar), 7.53 (1H, dd J 9.1, 4.5 Hz, Ar), 7.17 (2H, m, Ar), 7.07 (1H, dd J 9. 1, 2.6 Hz, Ar ), 7.03 (2H, m, Ar), 6.96 (1H, t J 7.3 Hz, Ar), 5.03 (2H, s, CH2C02H), 2.48 (3H, s, CH3); Tr = 1.28 min (96%), m / z (ES +) (M + H) + 363.25. Compound 19-Acid [3- (3,4-dichloro-benzylsulfamoyl) -5-f-luoro-2-methyl-indol-1-yl] -acetic dH (400 MHz, de-DMSO) 7.92 (1H, broad, S02NH ), 7.47 (1H, dd J 10. 3, 2.6 Hz, Ar), 7.40 (1H, d J 8.3 Hz, Ar), 7.37 (1H, d J 1.7 Hz, Ar), 7.31 (1H, dd J 9.0, 4.6 Hz, Ar), 7.13 (1H, dd J 8.2, 2.0 Hz, Ar), 6.96 (1H, td J 9.3, 2.7 Hz, Ar), 4.32 (2H, s, CH2C02H), 3.93 (2H, s, NCH2 ), 2.49 (3H, s, CH3); Tr = 1.43 min (97%), m / z (ES +) (M + H) + 445.15. Compound 20-Acid [5-f luoro-3- (3-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic dH (400 MHz, d6-DMS0) 10.22 (1H, s, S02NH), 7.60
(1H, dd J 9.9, 2.5 Hz, Ar), 7.50 (1H, dd J 9.1, 4.1 Hz, Ar), 7.05 (2H, m, Ar), 6.61 (2H, m, Ar), 6.50 (1H, d 8.7
Hz, Ar), 4.88 (2H, s, CH2C02H), 3.60 (3H, s, OCH3), 2.54
(3H, s, CH3); Tr = 1.28 min (100%), m / z (ES +) (M + H) +
393. 28. Compound 21-Acid (5-fluoro-2-methyl-3-m-tolylsulfamoyl-indol-1-yl) -acetic dH (400 MHz, d6-DMSO) 10.11 (1H, s, S02NH), 7.61
(1H, dd J 10.1, 2.6 Hz, Ar), 7.55 (1H, dd J 9.1, 4.5 Hz,
Ar), 7.08 (1H, dd J 9.2, 2.6 Hz, Ar), 7.03 (1H, d J 7.8,
Ar), 6.85-6.81 (2H, m, Ar), 6.76 (1H, d J 7.6 Hz, Ar), 5.08 (2H, s, CH2C02H), 2.50 (3H, s, CH3), 2.15 (3H, s,
ArCH3), Tr = 1.33 min (100%), m / z (ES +) (M + H) + 377.24. Compound 22-Acid (5-fluoro-2-methyl-3-p-tolylsulfamoyl-indol-1-yl) -acetic dH (400 MHz, d6-DMS0) 9.90 (1H, broad, S02NH), 7.55 (1H, dd J 10.2, 2.6 Hz, Ar), 7.32 (1H, dd J 9.1, 4. 6, Ar), 6.94 (5H, m, Ar), 4.31 (2H, s, CH2C02H), 2.45 (3H, s, CH3) , 2.15 (3H, s, CH3), Tr = 1.33 min (100%), / z (ES +) (M + H) + 377.25.
Compound 23-Acid [3- (4-Chloro-benzylsulfonyl) -5-f-luoro-2-methyl-indol-1-yl] -acetic dH (400 MHz, d6-DMS0) 8.04 (1H, t J 5.9 Hz , NH), 7.58-7.51 (2H,, Ar), 7.25 (2H, d J 8.6 Hz, Ar), 7.18 (2H, d J 8.6 Hz, Ar), 7.07 (1H, td J 9. 5, 2.7 Hz , Ar),
. 07 (2H, s, CH2C02H), 3.93 (2H, d J 6.3 Hz, NCH2) 2.56 (3H, s, CH3); Tr = 1.38 min (91%), m / z (ES +) (M + H) + 411.07. Compound 24-Acid [3- (Benzyl-methyl-sulfamoyl) -5-f-luoro-2-methyl-indol-1-yl] -acetic dH (400 MHz, d6-DMS0) 7.52 (1H, dd J 10.0, 2.6
Hz, Ar), 7.46 (lH, dd J 8.9, 4.4 Hz, Ar), 7.39-7.28 (5H, m, Ar), 7.03 (1H, td J 9.4, 2.8 Hz, Ar), 4.46 (2H, s,
CH2C02H), 4.10 (2H, s, NCH2), 2.60 (3H, s, NCH3), 2.48 (3H, s, CH3); Tr = 1.43 min (100%), m / z (ES +) (M + H) + 391.15. Compound 25-Acid [5-fluoro-2-methyl-3- (pyridin-3-ylsulfamyl) -indol-1-yl] -acetic acid dH (400 MHz, de-DMSO) 10.42 (1H, s, S02NH), 8.25 (1H, d J 2.6 Hz, Ar), 8.19 (1H, d, 3.3 Hz, Ar), 7.59-7.55 (2H, m, Ar), 7.40 (1H, d J 8.3Hz, Ar), 7.24-7.21 (2H, m, Ar), 5.10 (2H, s, CH2C02H), 2.49 (3H, s, CH3); Tr = 0.96 min (100%), m / z (ES +) (M + H) + 364.1.
Example 5 - Measurement of Activity
CRTH2 Antagonists Materials and Methods Materials Calcium-3 dye was obtained from Molecular Devices (Wokingham, UK). The mono-poly resolution medium was obtained from Dainippon Pharmaceuticals (Osaka, Japan). The anti-CDl6 Macs anti microbeads were from Miltenyi biotec (Bisley, Surrey). ChemoTx plates were obtained from Neuroprobe (Gaithesburg, MD). The 96-well plates coated with poly-D-lysine were obtained from Greiner (Gloucestershire, UK). The [3H] PGD2 was from Amersham Biosciences (Buckinghamshire, UK). [3H] SQ29548 was obtained from Perkin Elmer Life Sciences (Buckinghamshire, UK). All other reagents were obtained from Sigma-Aldrich (Dorset, UK), unless otherwise indicated.
Methods Cell Culture Chinese hamster ovary cells were transfected with CRTH2 or DP receptors (CH0 / CRTH2 and CHO / DP) and were kept in culture in a humid atmosphere at 37 ° C (5% C02) in Minimum Essential Medium (MEM) ) supplemented with 10% fetal bovine serum, 2 M glutamine, and 1 mg ml "1 active G418 cells were passed every 2-3 days.For the radioligand binding assay, the cells were prepared in triple flasks layer or in 175 cm2 square flasks (for membrane preparation) For the calcium mobilization assay, the cells were grown in a 96-well plate 24 hours before the assay at a rate of 80,000 cells per well.
Preparation of cell membranes The membranes were prepared from cellular CHO / CRTH2 and CHO / DP, or from platelets (as sources of TP receptors). CHO cells that grew to confluence were washed with PBS and detached using a Versene solution (15 ml per flask). When the cells grew in 175 cm2 square flasks they were collected by detaching in PBS. The cell suspensions were centrifuged (1,700 rpm, 10 min, 4 ° C) and resuspended in 15 ml of buffer (IxHBSS, supplemented with 10 mM HEPES, pH 7.3). The cell suspensions were then homogenized using an Ultra Turrax set at 4-6 for 20 s. The homogenate was centrifuged at 1,700 rpm for 10 min and the supernatant was collected and centrifuged at 20,000 rpm for 1 h at 4 ° C. The resulting pellet was resuspended in buffer and stored at -80 ° C in 200-500 μl aliquots. The protein concentration was determined by the method of Bradford (1976), using bovine serum albumin as standard. The platelets were washed by centrifugation at 600xg for 10 min and resuspended in ice-cold assay buffer (10 mM Tris-HCl, pH 7.4, 5 mM Glucose, 120 mM NaCl, 10 μM indomethacin) and centrifuged directly at 20,000 rpm for 30 minutes. min at 4 ° C. The resulting pellet was treated as described above.
Radioligand Binding Assays [3H] PGD2 (160 Ci / mmol) binding experiments were performed on membranes prepared as described above. The tests were carried out in a final volume of 100 μl of buffer (1 × HBSS / 10 mM HEPES, pH 7.3). Cell membranes (15 μg). 15mg of cell membranes were preincubated at room temperature with varying concentrations of competent ligand for 15 min. Then [3H] PGD2 (mol, final concentration) and the incubation was continued for 1 hour more at room temperature. The reaction was terminated by the addition of 200 μl of ice-cold assay buffer to each well, followed by rapid filtration through Whatman GF / B glass fiber filters using a Unifilter cell harvester (PerkinElmer Life Sciences) and six washes. 300 μl of ice-cooled buffer. The Unifilter plates were dried at room temperature for at least 1 h and the radioactivity retained on the filters was determined in a Beta Trilux counter (PerkinElmer Life Sciences), following the addition of 40 μl of Optiphase Hi-Safe 3 liquid flasher (Wallac). No non-specific binding was defined in the presence of 10 μ of unlabeled PGD2. The tests were carried out in duplicate. The results of the radioligand binding experiments at the CRTH2 and DP receptors are shown in Table 1. The results shown in Table 1 demonstrate that the compounds of the general formula (I) have high affinity for the CRTH2 receptor. In those cases where a comparison was made, the affinity of the compounds of the general formula of the compounds (I) is much higher than CRTH2 than for the DP receptor.
Table 1 - Radioligand binding data (Ki on the CRTH2 receptor and the DP receptor) Ki Ki binding compound of the CRTH2 nM DP junction μM 192 > 10 75 > 10 2000 ND 2300 ND 89 > 10 209 ND 54 ND 249 ND 254 > 10 10 ND 11 51 > 10 12 45 > 10 13 182 ND 14 225 ND 15 278 > 10 16 771 > 10 17 1450 > 10 18 236 > 10 19 181 > The radioligand binding of the TP receptor was carried out on membranes prepared from platelets. 15-40 μg of protein were pre-incubated with varying concentrations of competent ligand for 15 min at room temperature in assay buffer (10 mM Tris-HCl, pH 7.4, 5 M glucose, 120 mM NaCl, 10 μM indomethacin). Then [3H] SQ29548 (38 Ci / mmol, final concentration of 10 nM) was added and incubation was continued for an additional 30 min at room temperature. The reaction was terminated by the addition of 200 μl of ice-cold assay buffer to each well, followed by rapid filtration through Whatman GF / C glass fiber filters using a Unifilter cell harvester (PerkinElmer Life Sciences) followed by six washed 300 μl of ice-cooled buffer. The radioactivity was determined as described above. All the compounds studied in that assay were bound to the TP receptor with low affinity (Ki> 10 μM). The compounds of general formula (I) were bound to the CRTH2 receptor expressed in CHO cells with a variable affinity range of very high to moderate. Indeed, Ki values determined in the competition against [3 H] PGD2 ranged from 500 pM to 1 μM. The compounds of general formula (I) had no activity (or very weak activity) at the DP and TP receptors. The binding selectivity of the compounds of general formula (I) for the CRTH2 receptor was greater than 200 times for the CRTH2 receptor, compared to that of the DP and TP receptors.
Calcium mobilization assay Cells were seeded onto 96-well plates coated with poly-D-lysine at a density of 80,000 cells per well and incubated at 37 ° C overnight to allow the cells to adhere. The cells were washed twice with HBSS and incubated for 1 h at 37 ° C in 100 μl of HBSS and 100 μl of calcium-3-dye solution (Molecular Devices), supplemented with probenecid 4mM. Changes in fluorescence were verified over a 50 s time course with addition of agonist at 17 s using a Flexstation (Molecular Devices).
Effect of CRTH2 agonists on calcium mobilization of C-O-CRTH2 cells PGD2 produced a dose-dependent increase in intracellular Ca2 + mobilization in CH0 / CRTH2 cells, with an EC50 = 2.4 + 0.5nM (n = 3) (Figure 1).
Effect of the compounds of general formula (I) on the mobilization of calcium induced by PGD? The flow of Ca2 + stimulated by PGD2 was completely inhibited by the compounds of general formula (I) and the IC 50 value for each compound in the calcium assay was comparable to its Ki value in the radioligand binding. The IC 50 values of the compounds of general formula (I) ranged from 5 nM to 1 μM. The results for the different compounds of general formula (I) are shown in Table 2. The increase in the dose of the compounds of general formula (I) produced a dose-dependent and parallel deviation of the dose response curve of PGD2 in CH0 / CRTH2 cells, thus indicating that the compounds are repetitive antagonists of CRTH2. The antagonistic effect of the compounds of formula (I) appears to be selective for CRTH2 since no inhibitory effect was observed with the Ca2 + flux stimulated by ATP in CHO / CRTH2 cells.
Table 2 - Inhibition of calcium flux induced by PGD2
Claims (30)
- NOVELTY OF THE INVENTION Having described the invention as above, property is claimed as contained in the following:
- CLAIMS A compound of general formula (I) characterized in that R1, R2, R3 and R4 are independently hydrogen, halo, C? -C6 alkyl, -O (C? -C6 alkyl), -CON (R9) 2, -SOR9, -S02R9, -S02N (R9) ) 2, -N (R9) 2, -NR9COR9, -C02R9, -COR9, -SR9, -OH, -N02 or -CN; each R9 is independently hydrogen or C6-C6 alkyl; R5 and R6 are each independently hydrogen, or C? -C6 alkyl or together with the carbon atom which is attached form a C3-C7 cycloalkyl group;
- R7 is hydrogen or C? -C6 alkyl is 1 or 2; X is a bond, when n is 2, X may also be a group NR9; where R9 is as defined above; when X is a bond R8 is a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 5 alkynyl, biphenyl or a bicyclic heteroaryl group or 9-14 member tricyclic; when X is a group NR9 and R8 can additionally be phenyl, naphthyl or a 5-7 membered hetero aromatic ring; and the R8 group is optionally substituted with one or more substituents selected from halo, Cx-Ce alkyl, -O (Ci-Cß) alkyl / aryl, -O-aryl, heteroaryl, -O-heteroaryl, -SOR9, - S02R9, S02N (R9) 2, -NR9COR9, -C02R9, -COR9, -SR9, -OH, -N02O-CN; where R9 is as defined above; or a salt, hydrate, solvate, complex or prodrug thereof. 2. A compound of general formula (II): characterized in that R1, R2, R3, R4, R5, R6, n, X, R7 and R8 are as defined for the general formula (I); R10 is C? -C6 alkyl, aryl, (CH2) mOC (= 0) C? -C6 alkyl, (CHZJH? R11) ^ CH ((CH2) mO (C = 0) R12) 2; m is 1 or 2; R11 is hydrogen or methyl; R12 is C? -C? Alkyl. 3. The compound according to claim 1 or claim 2, characterized in that, independently or in any combination: R1 is halo or hydrogen; R2 is halo or hydrogen; R3 is halo or hydrogen; R4 is halo or hydrogen;
- 4. The compound according to any of claims 1 to 3, characterized in that R1, R3 and R4 are hydrogen and R2 is halo.
- 5. The compound according to claim 4, characterized in that R2 is fluorine.
- 6. The compound according to any of claims 1 to 5, characterized in that R5 and R6 are each independently hydrogen or C? _C alkyl.
- 7. The compound according to claim 6, characterized in that at least one of R5 and R5 are hydrogen.
- 8. The compound according to claim 7, characterized in that both of R5 and R6 are hydrogen.
- 9. The compound according to any of claims 1 to 8, characterized in that R7 is H or Ci-Cß alkyl.
- 10. The compound according to claim 9, characterized in that R7 is methyl.
- 11. The compound according to any of claims 1 to 10, characterized in that n is 2.
- 12. The compound according to any of claims 1 to 11, characterized in that X is a bond and R8 is C-Ce alkyl. , biphenyl or a bicyclic heteroaryl group, any of which may be substituted by halogen, phenyl, -C02R9 CON (R9) 2 or -S02R9, where R9 is as defined above.
- 13. A compound according to claim 12, characterized in that R8 is C-C4 alkyl, biphenyl, a bicyclic heteroaryl group or a 5-7 membered heterocyclic ring, any of which may be substituted with phenyl, -C02R9 CON (R9) ) 2 or -S02R9, where R9 is H or C? -C4 alkyl. A compound according to any of claims 1 to 11, characterized in that X is NR9, R9 is H or methyl and R8 is: phenyl optionally substituted with one or more halo groups, C-Ce alkyl or -O (alkyl) of C? -C6) Ci-Ce alkyl, optionally substituted with aryl; or heteroaryl. 15. The compound according to claim 14, characterized in that R8 is phenyl, benzyl or pyridyl, any of which may be optionally substituted with one or more halo, methyl or methoxy groups. 16. [3- (Butan-1-sulfonyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid. 3- (Biphenyl-4-sulfonyl) -5-fluoro-2-methyl-indole acid -1-yl] - acetic acid (3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid (3-carbamoylmetanesulfonyl-5-fluoro-2-methyl-indol-1-yl) - acetic acid [5-Fluoro-3- (2-methanesulfonyl-ethanesulfonyl) -2-methyl-indol-1-yl] -acetic acid [3- (Benzothiazole-2-sulfonyl) -5-fluoro-2-methyl-indole -1-yl] - acetic acid [3- (Benzothiazol-2-sulfinyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid [5-fluoro-2-methyl-3- (quinoline- 2- sulfonyl) -indol-1-yl] -acetic acid [5-Fluoro-2-methyl-3- (quinolin-8-ylsulfonyl) -indol-1-yl] -acetic acid (5-fluoro-2-methyl) -3-phenylmetanesulfonyl-lH-indol-1-yl) -acetic acid [3- (4-Chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid [3- (3- Chloro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid [3- (4-Fluoro-phenylsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid [3- (2-Chloro-fe nilsulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid (3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl) -acetic acid [5-fluoro-3- ( 2-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid [5-Fluoro-3- (4-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid (5-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid -fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl) -acetic acid [3- (3,4-Dichloro-benzylsulfamoyl) -5- fluoro-2-methyl-indol-l-yl] -acetic acid [5-fluoro-3- (3-methoxy-phenylsulfamoyl) -2-methyl-indol-1-yl] -acetic acid (5-fluoro-2-methyl-3-m-tolylsulfamoyl-indol-1-yl) - acetic Acid (5-fluoro-2-methyl-3-p-tolylsulfamoyl-indol-1-yl) -acetic acid [3- (4-Chloro-benzylsulfamoyl) -5-fluoro-2-methyl-indole-1-yl ] -acetic acid [3- (benzyl-methyl-sulfamoyl) -5-fluoro-2-methyl-indol-1-yl] -acetic acid [5-fluoro-2-methyl-3- (pyridin-3-ylsulfamoyl)] -indol-1-il] -acetic; or the alkyl esters of C? -C6, aryl, (CH2) OC (= 0) C, -alkyl of C? -C6, (CH2) mN (R11) 2, CH ((CH2) mO (C = 0 ) R12) 2 of any of the foregoing; where m is 1 or 2; R11 is hydrogen or methyl; R12 is C? -C18 alkyl. 17. A process for the preparation of a compound of general formula (I) according to any of claims 1 to 13 or 16, wherein n is 1 or 2 and X is a bond, the process is characterized in that it comprises a compound of general formula (la), which is a compound of general formula (I) wherein n is = and X is a bond, by oxidation with a suitable oxidizing agent. 18. A process for the preparation of a compound of formula (I) according to any of claims 1 to 16, characterized in that the process comprises reacting a compound of general formula (II) according to claim 2 and wherein R10 is Ci-Cß alkyl with a base. 19. The compound according to any of claims 1 to 16 for use in medicine. The compound according to any one of claims 1 to 16 for use in the treatment of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis , eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other diseases mediated by PGD2, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematosus, psoriasis, acne , multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive pulmonary disease or rheumatoid arthritis, psoriatic arthritis and osteoarthritis. 21. The use of a compound according to any of claims 1 to 16 in the preparation of an agent for the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including dermatitis) contact), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other diseases mediated by PGD2, for example, autoimmune diseases such as the syndrome hyper IgE and systemic lupus erythematosus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease or rheumatoid arthritis, psoriatic arthritis and osteoarthritis. 22. A pharmaceutical composition, characterized in that it comprises a compound according to any of claims 1 to 16 together with a pharmaceutical excipient or carrier. 23. The composition according to claim 22, characterized in that it is formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye, buccal and sublingual drops) vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal). 24. A composition according to claim 23, characterized in that it is formulated for oral, nasal, bronchial or topical administration. 25. The composition according to any of compositions 22 to 24 characterized in that it contains one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD at the CRTH2 receptor. 26. The composition according to claim 25, characterized in that the additional active agents are selected from: ß2 agonists such as salmeterol; corticosteroids such as fluticasone; antihistamines such as loratidine; leukotriene antagonists such as montelukast; therapies with anti-IgE antibody such as omalizumab; anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis); antifungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of inflammatory skin disease; other PGD2 antagonists that act on other receptors as DP antagonists; phosphodiesterase type 4 inhibitors such as cilonilast; drugs that modulate the production of citone as inhibitors of the TNFa converting enzyme (TACE); drugs that modulate the activity of the Th2 cytokines IL-4 and IL-5 as blocking monoclonal antibodies and soluble receptors; PPAR-agonists and such as rosiglitazone; 5-lipoxygenase inhibitors such as zileuton. 27. A process for the preparation of a pharmaceutical composition according to any of claims 22 to 26, characterized in that it comprises binding a compound according to any of claims 1 to 16 in conjunction with an association with a support or vehicle pharmaceutically or veterinarily acceptable. 28. A product, characterized in that it comprises a compound according to any of claims 1 to 16 and one or more of the agents listed in claim 26 with a combined preparation for simultaneous, separate or sequential use in the treatment of a disease or condition mediated by the action of PGD at the CRTH2 receptor. 29. The use according to claim 21, wherein the agent also comprises the additional active agent useful for the treatment of diseases and conditions mediated by PGD2 at the CRTH2 and / or DP receptor. 30. Use in accordance with the claim 29, where the additional active agent is one of the agents listed in claim 26.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0324084.3 | 2003-10-14 | ||
GB0400716.7 | 2004-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06004136A true MXPA06004136A (en) | 2007-04-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070232681A1 (en) | Compounds Having Crth2 Antagonist Activity | |
EP1856045B1 (en) | 1-acetic acid-indole derivatives with pgd2 antagonist activity | |
AU2004287245B2 (en) | Use of CRTH2 antagonist compounds in therapy | |
AU2009204700B2 (en) | Compounds having CRTH2 antagonist activity | |
WO2005121141A1 (en) | Pyrrolopyridine derivatives and use thereof for treating diseases mediated by prostaglandin d2 (pgd2) | |
US8404856B2 (en) | Non-nucleoside reverse transcriptase inhibitors | |
GB2422831A (en) | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor | |
WO2005040112A1 (en) | Compounds with pgd2 antagonist activity | |
GB2422830A (en) | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor | |
GB2407318A (en) | Substituted Indol-3-yl acetic acid derivatives | |
GB2422829A (en) | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor | |
JP2000502724A (en) | Use of indazole derivatives and inhibitors as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) production inhibitors | |
WO2005035501A1 (en) | Novel olefin derivative | |
JP7043483B2 (en) | Bicyclic proline compound | |
AU2004232483B2 (en) | 7-azaindoles and use thereof as therapeutic agents | |
MXPA06004136A (en) | Compounds having crth2 antagonist activity | |
KR20070032264A (en) | Compounds having crth2 antagonist activity | |
MXPA06004506A (en) | Use of crth2 antagonist compounds in therapy |